Peter C. Everett MD

Assistant Professor, Hematology & Medical Oncology

818 Harrison Ave | (617) 638-7526
Peter Everett
Sections

Hematology & Medical Oncology

Centers

Evans Center for Interdisciplinary Biomedical Research

Biography

Dr. Peter Everett is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine (BUSM) and a medical oncologist in the Section of Hematology and Medical Oncology at Boston Medical Center (BMC). He received his undergraduate degree from Cornell University and his medical degree from Chobanian and Avedisian School of Medicine. Following that, he completed training in Internal Medicine and a fellowship in Hematology and Medical Oncology at Boston Medical Center, where he also served as the Chief Fellow. Dr. Everett specializes in head, neck and thoracic oncology.

Websites

BU Profile

Education

Medicine-Internal, MD, Boston University School of Medicine

Applied Physics, BS, Cornell University

Publications

Published on 6/8/2023

Qureshi MM, Lin Y, Moeller AR, Yan SX, Dyer MA, Suzuki K, Everett P, Litle V, Truong MT, Mak KS. Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer. J Surg Oncol. 2023 Oct; 128(5):781-789. PMID: 37288789.

Published on 8/1/2022

Lee MH, Qureshi MM, Suzuki K, Everett P, Tapan U, Mak KS. Small cell lung cancer in young patients: trends in sociodemographic factors, diagnosis, treatment, and survival. J Thorac Dis. 2022 Aug; 14(8):2880-2893. PMID: 36071763.

Published on 10/19/2021

Hanna GJ, O'Neill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478. PMID: 34667025.

Published on 8/3/2021

Freydman J, Henshaw L, Patel JV, Smith CE, Everett PC. Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC. Ann Pharmacother. 2022 04; 56(4):503-504. PMID: 34344199.

Published on 10/20/2020

Tapan U, Furtado VF, Qureshi MM, Everett P, Suzuki K, Mak KS. Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC. JTO Clin Res Rep. 2021 Jan; 2(1):100109. PMID: 34589974.

Published on 1/9/2019

Shah NK, Qureshi MM, Dyer MA, Patel SA, Kim K, Everett PC, Grillone GA, Jalisi SM, Truong MT. Optimal sequencing of chemoradiotherapy for locally advanced laryngeal cancer. Laryngoscope. 2019 10; 129(10):2313-2320. PMID: 30628077.

Published on 2/8/2018

Kirke DN, Qureshi MM, Kamran SC, Ezzat W, Jalisi S, Salama A, Everett PC, Truong MT. Role of adjuvant chemoradiotherapy in T4N0 stage IV head and neck cancer: A National Cancer Database analysis. Head Neck. 2018 06; 40(6):1174-1184. PMID: 29417687.

Published on 4/25/2012

Tan JN, Kroll MH, O'Hara CJ, Everett PC, Erdogan E. Gamma heavy chain disease in a patient with underlying lymphoplasmacytic lymphoma of the thyroid. Report of a case and comparison with other reported cases with thyroid involvement. Clin Chim Acta. 2012 Oct 9; 413(19-20):1696-9. PMID: 22561184.

Published on 9/2/2010

Ren JG, Seth P, Everett P, Clish CB, Sukhatme VP. Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2. PLoS One. 2010 Sep 02; 5(9). PMID: 20824065.

Published on 1/1/2007

Everett PC, Meyers JA, Makkinje A, Rabbi M, Lerner A. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol. 2007 Jan; 82(1):23-30. PMID: 16947318.

View full list of 16 publications.